JPH10265454A - ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 - Google Patents

３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤

Info

Publication number
JPH10265454A
JPH10265454A JP10016362A JP1636298A JPH10265454A JP H10265454 A JPH10265454 A JP H10265454A JP 10016362 A JP10016362 A JP 10016362A JP 1636298 A JP1636298 A JP 1636298A JP H10265454 A JPH10265454 A JP H10265454A
Authority
JP
Japan
Prior art keywords
oxo
dihydroxy
group
enoic acid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP10016362A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10265454A5 (https=
Inventor
Toru Maruyama
透 丸山
Shuichi Ouchida
修一 大内田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Priority to JP10016362A priority Critical patent/JPH10265454A/ja
Publication of JPH10265454A publication Critical patent/JPH10265454A/ja
Publication of JPH10265454A5 publication Critical patent/JPH10265454A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Microscoopes, Condenser (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP10016362A 1997-01-27 1998-01-12 ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 Withdrawn JPH10265454A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP10016362A JPH10265454A (ja) 1997-01-27 1998-01-12 ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2719897 1997-01-27
JP9-27198 1997-01-27
JP10016362A JPH10265454A (ja) 1997-01-27 1998-01-12 ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤

Publications (2)

Publication Number Publication Date
JPH10265454A true JPH10265454A (ja) 1998-10-06
JPH10265454A5 JPH10265454A5 (https=) 2005-07-28

Family

ID=12214403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10016362A Withdrawn JPH10265454A (ja) 1997-01-27 1998-01-12 ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤

Country Status (8)

Country Link
US (1) US5892099A (https=)
EP (1) EP0855389B1 (https=)
JP (1) JPH10265454A (https=)
AT (1) ATE218543T1 (https=)
DE (1) DE69805665T2 (https=)
DK (1) DK0855389T3 (https=)
ES (1) ES2182220T3 (https=)
PT (1) PT855389E (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024647A1 (en) * 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
US6410591B1 (en) 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US6538018B1 (en) 2001-06-14 2003-03-25 Allergan, Inc. 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
JP2005139207A (ja) * 1999-11-24 2005-06-02 Ono Pharmaceut Co Ltd 骨量低下疾患治療剤
WO2006016695A1 (ja) * 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
US7872045B2 (en) 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043275A (en) * 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
EP1121133A1 (en) * 1998-10-15 2001-08-08 Merck & Co., Inc. Methods for stimulating bone formation
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
CA2332375A1 (en) * 1999-03-16 2000-09-21 Masafumi Isogaya Cervical ripening agent and cervical ripening method
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
BR0015781A (pt) * 1999-11-24 2002-12-31 Ono Pharmaceutical Co Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
TWI247606B (en) * 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
IL141120A0 (en) * 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
GB0103269D0 (en) * 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
US20050222094A1 (en) * 2001-06-14 2005-10-06 Burk Robert M Treatment of inflammatory bowel disease
EP1490055A1 (en) * 2002-03-18 2004-12-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
AU2003224244A1 (en) * 2002-03-27 2003-10-13 Rosanto Pharmaceuticals Ltd Improvements in pharmaceutical compositions
AU2003233729B2 (en) 2002-06-06 2007-10-04 Merck Frosst Canada Ltd 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
WO2004073589A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
EP1742662A2 (en) * 2004-05-03 2007-01-17 Astellas Pharma Inc. Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases
WO2006047466A2 (en) 2004-10-21 2006-05-04 Duke University Ophthamological drugs
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
US20080167377A1 (en) 2006-12-15 2008-07-10 Alessandra Gaiba Novel compounds
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
CN107849072B (zh) 2015-06-12 2020-12-15 西蒙弗雷泽大学 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57108065A (en) * 1980-12-26 1982-07-05 Teijin Ltd 7-thiaprostaglandin e1 derivative, its preparation, and blood platelet coagulation inhibiting agent containing said derivative as active component
EP0051284B1 (en) * 1980-10-31 1985-01-09 Teijin Limited Novel thiaprostaglandin e1 derivatives, process for production thereof, and pharmaceuticals containing these compounds
JPS58110562A (ja) * 1981-12-25 1983-07-01 Teijin Ltd 新規な７−チアプロスタグランジンｅ↓１誘導体類、それらの製造方法及びそれらを活性成分とする薬剤
JPS58148857A (ja) * 1982-02-26 1983-09-05 Teijin Ltd 新規な１３，１４−ジヒドロ−７−チアプロスタグランジンｅ↓１類およびその製造方法

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005139207A (ja) * 1999-11-24 2005-06-02 Ono Pharmaceut Co Ltd 骨量低下疾患治療剤
WO2002024647A1 (en) * 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
US6410591B1 (en) 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US6538018B1 (en) 2001-06-14 2003-03-25 Allergan, Inc. 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US6956057B2 (en) 2001-06-14 2005-10-18 Allergan, Inc. EP4 agonists as agents for lowering intraocular pressure
US7872045B2 (en) 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment
WO2006016695A1 (ja) * 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤

Also Published As

Publication number Publication date
DE69805665T2 (de) 2002-11-21
EP0855389A3 (en) 1999-06-16
DE69805665D1 (de) 2002-07-11
DK0855389T3 (da) 2002-10-14
ES2182220T3 (es) 2003-03-01
PT855389E (pt) 2002-10-31
ATE218543T1 (de) 2002-06-15
EP0855389B1 (en) 2002-06-05
US5892099A (en) 1999-04-06
EP0855389A2 (en) 1998-07-29

Similar Documents

Publication Publication Date Title
JPH10265454A (ja) ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
JP4044967B2 (ja) １１，１５−ｏ−ジアルキルプロスタグランジンｅ誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
JP3174563B2 (ja) ５−チア−ω−置換フェニル−プロスタグランジンＥ誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
US6262293B1 (en) ω-Cycloalkly-prostaglandin e2 derivatives
US6235780B1 (en) ω-cycloalkyl-prostaglandin E1 derivatives
JPWO1998034916A1 (ja) １１，１５−ｏ−ジアルキルプロスタグランジンｅ誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
JPWO2000003980A1 (ja) ５−チア−ω−置換フェニル−プロスタグランジンＥ誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
JP2691679B2 (ja) オキシム誘導体およびそれを含有する医薬品
JP3162668B2 (ja) ω−シクロアルキル−プロスタグランジンＥ２誘導体
JPH0149264B2 (https=)
JP2001527063A (ja) ω−シクロアルキル−プロスタグランジンＥ２誘導体
JP4029251B2 (ja) ω−シクロアルキル−プロスタグランジンＥ２誘導体
US6639111B2 (en) 5-thia-ω-(substituted phenyl)-prostaglandin E alcohols, process for preparing the alcohols and pharmaceutical preparations containing the same as the active ingredient
JP4123568B2 (ja) ６−オキソ−ｐｇｅ１化合物、それらの製造方法およびそれらを有効成分として含有するプロスタグランジンｅ２受容体作働薬
JP4193197B2 (ja) ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
JPS62277352A (ja) 新規な６−ケト−プロスタグランジンｅ１誘導体、それらの製造方法およびそれらを有効成分として含有する細胞障害治療剤
JP3703004B2 (ja) ５−チア−ω−置換フェニル−プロスタグランジンＥ誘導体
JP2000095755A (ja) ω―シクロアルキル―プロスタグランジンＥ１誘導体、その製造方法およびその誘導体を有効成分とする医薬組成物
JP3140999B2 (ja) ベンゼンスルフォンアミド化合物、それらの製造方法およびそれらを有効成分として含有するプロスタグランジンｅ２受容体拮抗剤
JPS5892637A (ja) 新規なシス―ビシクロ［３．３．０］オクタン誘導体、当該誘導体を含有する血小板凝集抑制剤および血圧降下剤ならびに当該誘導体の製造方法
JP2000103778A (ja) ベンゼンスルフォンアミド化合物、それらの製造方法およびそれらを有効成分として含有するプロスタグランジンｅ２受容体拮抗剤
JP2002161082A (ja) プロスタグランジン誘導体
JPH03223244A (ja) ５―ヘテロ―６―オキソ―ｐｇｅ誘導体、それらの製造方法およびそれらを含有する薬剤
JPWO2001049661A1 (ja) ５−チア−ω−置換フェニル−プロスタグランジンＥ−アルコール、それらの製造方法およびそれらを有効成分として含有する薬剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041213

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060929